Welcome to "Medical News Updates," the go-to channel for anyone eager to understand complex medical news in a straightforward, simplified manner. Our mission is to break down the latest health studies and medical news into easy-to-digest information that makes sense to everyone, especially those without a medical background.
What We Offer:
Why Subscribe?
Welcome to "Medical News Updates," the go-to channel for anyone eager to understand complex medical news in a straightforward, simplified manner. Our mission is to break down the latest health studies and medical news into easy-to-digest information that makes sense to everyone, especially those without a medical background.
What We Offer:
Why Subscribe?
In today's episode, we discuss an important alert from the WHO regarding semaglutide medicines like Ozempic, Rybelsus, and Wegovy, which are used for type 2 diabetes and weight management. A rare but serious side effect called non-arteritic anterior ischemic optic neuropathy (NAY-on), leading to sudden vision loss, has been linked to these drugs. We review what the European Medicines Agency has found, the risks involved, and what patients should do if they experience vision changes. Awareness and prompt action are crucial. Learn more about how to manage these risks while benefiting from these medications.
00:00 Introduction to Today's Episode
00:01 Understanding Semaglutide Medicines
00:17 Serious Side Effect Alert: NAY-on
00:49 Risk Assessment and Recommendations
01:45 Guidance for Patients on Semaglutide
02:19 Conclusion